Improvement in left ventricular hypertrophy and left ventricular diastolic function following verapamil therapy in mild to moderate hypertension.
We evaluated the effect of verapamil therapy on left ventricular hypertrophy and left ventricular diastolic function in 13 patients with mild to moderate hypertension. Left ventricular hypertrophy was determined by M-mode echocardiographic measurements of interventricular septal thickness (IVST), posterior wall thickness (PWT) and left ventricular mass index (LVMI) both before (T0) and after 3 months (T3) of verapamil therapy. Left ventricular diastolic transmitral flow was measured by pulsed Doppler indices of early (E) and atrial (A) velocity, E/A ratio, total area (Ta), A area (Aa), Aa/Ta ratio, E-pressure half-time (E-PHT). A-pressure half-time (A-PHT) and E-PHT/A-PHT ratio both before and after 3 months of verapamil therapy. No significant changes occurred in mean heart rate, systolic function or body weight. We conclude that 3 months' therapy with verapamil resulted in an improvement in left ventricular hypertrophy and left ventricular diastolic function and a normalization of blood pressure, without a corresponding deterioration in left ventricular systolic function.
Granier
P
P
Service de Cardiologie, Hôpital Purpan, Toulouse, France.
Douste-Blazy
M Y
MY
Tredez
P
P
Conte
D
D
Galinier
F
F
D000328:Adult; D000368:Aged; D006332:Cardiomegaly / Q000188:drug therapy*; D003971:Diastole; D015150:Echocardiography, Doppler / Q000379:methods; D006346:Heart Septum / Q000473:pathology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008875:Middle Aged; D016277:Ventricular Function, Left / Q000187:drug effects; D014700:Verapamil / Q000627:therapeutic use*
D014700:Verapamil